Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Annals of Internal Medicine

• Publication date

  1989-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-110-9-704PMID 2930108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carcinoembryonic antigen assay in cancer of the colon and pancreas and other digestive tract disorders

  2005cited by this paper
• Serum CA 19‐9 concentrations and computed tomography findings in patients with pancreatic carcinoma

  1986cited by this paper
• Value of ultrasonographic examination combined with measurement of serum tumor markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter

  1986cited by this paper
• CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.

  1986cited by this paper
• CA 19‐9 and carcinoembryonic antigen in pancreatic cancer diagnosis

  1986cited by this paper
• CA 19‐9 and pancreatic adenocarcinoma

  1986cited by this paper
• Values of CA 19‐9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor

  1985cited by this paper
• Measurement of a monoclonal‐antibody‐defined antigen (CA 19‐9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigen

  1985cited by this paper
• CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.

  1985cited by this paper
• Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2.

  1985cited by this paper
• Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.

  1985cited by this paper
• A clinical evaluation of carbohydrate antigen 19‐9 and carcinoembryonic antigen in patients with pancreatic carcinoma

  1985cited by this paper
• Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.

  1985cited by this paper
• Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma.

  1984cited by this paper
• Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bank

  1984cited by this paper
• Characterization of monoclonal antibodies to serum galactosyltransferase.

  1984cited by this paper
• Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.

  1983cited by this paper
• Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

  1983cited by this paper
• A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

  1982cited by this paper
• Galactosyltransferase isoenzyme II in the detection of pancreatic cancer: comparison with radiologic, endoscopic, and serologic tests.

  1981cited by this paper
• Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer.

  1980cited by this paper
• Selectivity of the micro‐leukocyte adherence inhibition assay in pancreatic cancer

  1979cited by this paper
• Immunologic studies on a pancreatic oncofetal protein.

  1978cited by this paper
• Purification, partial characterization, and clinical evaluation of a pancreatic oncofetal antigen.

  1978cited by this paper
• Elevated serum ribonuclease in patients with pancreatic cancer.

  1976cited by this paper
• Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer

  1973cited by this paper

• CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma

  2025cites this paper
• Paciente varón de 51 años con ictericia indolora, coluria, acolia y prurito de dos semanas de evolución

  2025cites this paper
• Ratiometric electrochemical aptasensor based on functionalized graphene nanocomposites for detection of CA19-9

  2025cites this paper
• Unlocking the potential of oncology biomarkers: advancements in clinical theranostics

  2024cites this paper
• Imaging Techniques and Biochemical Biomarkers: New Insights into Diagnosis of Pancreatic Cancer

  2024cites this paper
• Fluorescence/electrochemical dual-mode strategy for Golgi protein 73 detection based on molybdenum disulfide/ferrocene/palladium nanoparticles and nitrogen-doped graphene quantum dots

  2024cites this paper
• Progress on diagnostic and prognostic markers of pancreatic cancer

  2023cites this paper
• DNA nanoprobes for detection and imaging of glycoproteins

  2023cites this paper
• Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection

  2023cites this paper
• Clinical Clues of Pre-Symptomatic Pancreatic Ductal Adenocarcinoma Prior to Its Diagnosis: A Retrospective Review of CT Scans and Laboratory Tests

  2022cites this paper
• Electrochemical immunosensor for point-of-care quantitative detection of tumor markers based on personal glucometer

  2022cites this paper
• Patients with Type 2 Diabetes Mellitus Accompanied by Elevated Serum CA19-9 Associated Not with Pancreatic Cancer but Interstitial Lung Disease

  2022cites this paper
• Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma.

  2022cites this paper
• A radiomics model that predicts lymph node status in pancreatic cancer to guide clinical decision making: A retrospective study

  2021cites this paper
• Pancreatic Cancer Classification Using the Kernel-based Support Vector Machine (KSVM)

  2021cites this paper
• Biliary Strictures: Etiologies and Medical Management

  2021cites this paper
• Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis

  2021cites this paper
• β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma

  2021cites this paper
• Assessment of the utility of the serum CA 19-9 in between benign and malignant pancreatic disease a study of 50 cases

  2021cites this paper
• Overview of Pancreatic Masses and Cystic Lesions

  2021cites this paper
• A review of response in neoadjuvant therapy for exocrine pancreatic cancer

  2021cites this paper
• Cáncer de páncreas

  2021cites this paper
• Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis.

  2020cites this paper
• Prognostic and predictive factors in pancreatic cancer

  2020cites this paper
• Liver Abscess: A Wolf in Sheep’s Clothing

  2020cites this paper
• High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer

  2020cites this paper
• Isolation of exosomes from whole blood by a new microfluidic device: proof of concept application in the diagnosis and monitoring of pancreatic cancer

  2020cites this paper
• Recent advances in mass spectrometry based clinical proteomics: applications to cancer research

  2020cites this paper
• Cancers du pancréas exocrine

  2020cites this paper
• Diagnostic strategy with a solid pancreatic mass.

  2019cites this paper
• Tumor Markers in GI and HPB Cancers

  2019cites this paper
• Special Issue: Cancer Biomarkers and Targets in Digestive Organs

  2019cites this paper
• GI Surgery Annual

  2019cites this paper
• Pancreatic and Ovarian Cancer Biomarkers

  2019cites this paper
• Pancreatic Adenocarcinoma

  2019cites this paper
• Prognostic Biomarker Identification for Pancreatic Cancer by Analyzing Multiple mRNA Microarray and microRNA Expression Datasets

  2019cites this paper
• Probing Glycoforms of Individual Proteins Using Antibody-Lectin Sandwich Arrays

  2019cites this paper
• Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: A systematic literature review

  2019cites this paper
• Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop.

  2018cites this paper
• Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer

  2018cites this paper
• New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment

  2018cites this paper
• CT combined with tumor markers in the diagnosis and prognosis of hepatocellular carcinoma.

  2018cites this paper
• Role of ca 19-9 as a tumor marker in diagnosis and prognosis of pancreatic carcinoma and cholangiocarcinoma (A study of 46 cases)

  2017cites this paper
• Aus der Klinik für Allgemein-, Viszeral- und Gefäßchirurgie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor in pancreatic ductal adenocarcinoma

  2017cites this paper
• Current and future therapies for advanced pancreatic cancer

  2017cites this paper
• A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi Project

  2017cites this paper
• Regional immunotherapy for liver and peritoneal metastases

  2017cites this paper
• Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study.

  2017cites this paper
• Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression

  2017cites this paper
• Pathology and Molecular Pathology of Pancreatic Cancer

  2017cites this paper
• Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma

  2017influential citation
• Pancreatic Cancer with Normal CA 19-9 and Lewis Antigen Negative—Case Report

  2017cites this paper
• Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients.

  2017cites this paper
• Genetic correction improves prediction efficiency of serum tumor biomarkers on digestive cancer risk in the elderly Chinese cohort study

  2017cites this paper
• Endoscopic ultrasound-guided techniques for diagnosing pancreatic mass lesions: Can we do better?

  2016cites this paper
• Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.

  2016cites this paper
• Cancers du pancréas exocrine

  2016cites this paper
• Pancreatic adenocarcinoma.

  2016cites this paper
• [Peutz-Jeghers syndrome].

  2016cites this paper
• New-onset type 2 diabetes mellitus--A high-risk group suitable for the screening of pancreatic cancer?

  2016cites this paper
• Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

  2015cites this paper
• Diagnosis and staging of pancreatic cancer

  2015cites this paper
• Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

  2015cites this paper
• CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis

  2014cites this paper
• Strategies for early detection of resectable pancreatic cancer.

  2014cites this paper
• The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer

  2014cites this paper
• Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.

  2014cites this paper
• Pancreatic and ovarian cancer biomarkers

  2014cites this paper
• Deposited in DRO : 06 September 2017 Version of attached le : Accepted Version Peer-review status of attached

  2014cites this paper
• Thymic carcinoma : what ast er disease progression ?

  2014cites this paper
• Extremely high level of CA 19-9 in a patient with metastatic pancreatic cancer: second highest level of CA 19-9 in literature.

  2014cites this paper
• CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis

  2014cites this paper
• Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft

  2014cites this paper
• Quantitative Analysis of Single Amino Acid Variant Peptides Associated with Pancreatic Cancer in Serum by an Isobaric Labeling Quantitative Method

  2014cites this paper
• Glycoprotein Biomarker Panel for Pancreatic Cancer Discovered by Quantitative Proteomics Analysis

  2014cites this paper
• Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single Institution

  2013cites this paper
• Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas

  2013cites this paper
• Preoperative evaluation and management of the pancreatic head mass

  2013cites this paper
• Serum CA19-9 in patients with solid pancreatic mass

  2013cites this paper
• Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

  2013cites this paper
• The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

  2013cites this paper
• Ultradepletion of human plasma using chicken antibodies: a proof of concept study.

  2013cites this paper
• Neutrophil Gelatinase-Associated Lipocalin, Macrophage Inhibitory Cytokine 1, and Carbohydrate Antigen 19-9 in Pancreatic Juice: Pathobiologic Implications in Diagnosing Benign and Malignant Disease of the Pancreas

  2013cites this paper
• A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk

  2013cites this paper
• Pancreatic Ductal Adenocarcinoma is Associated with a Distinct Urinary Metabolomic Signature

  2013cites this paper
• The Role of Quantitative NPTX2 Hypermethylation as a Novel Serum Diagnostic Marker in Pancreatic Cancer

  2012cites this paper
• Pancreatic cancer: early detection, diagnosis, and screening

  2012cites this paper
• Evaluation of serum diagnosis of pancreatic cancer by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

  2012cites this paper
• The Impact Of Palliative Care on The Aggressiveness Of End-of-life Care In Patients With Advanced Pancreatic Cancer

  2012cites this paper
• Changes in miR-143 and miR-21 Expression and Clinicopathological Correlations in Pancreatic Cancers

  2012influential citation
• Liver Abscess With a Markedly High Level of Carbohydrate Antigen 19-9

  2012cites this paper
• Only women with symptoms need to have their breast implants removed, says government

  2012cites this paper
• The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

  2012cites this paper
• Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review

  2011cites this paper
• Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases

  2011cites this paper
• Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.

  2011cites this paper
• Transcriptional Profiling of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients Identifies Novel Genes with Potential Diagnostic Utility

  2011cites this paper
• Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer

  2011cites this paper
• Relationship of CA 19-9 with choledocholithiasis and cholangitis.

  2011cites this paper
• Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer.

  2010cites this paper